⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TLX News
Telix Pharmaceuticals Limited American Depositary Shares
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
globenewswire.com
NVS
TLX
PFE
EXEL
LLY
XNCR
BTE
ORIC
MRK
ABBV
BMY
AZN
AMGN
Telix and United Imaging Announce Strategic Theranostics Collaboration
globenewswire.com
TLX
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
globenewswire.com
TLX
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
globenewswire.com
TLX
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
globenewswire.com
TLX
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
globenewswire.com
TLX
EDAP
PROF
EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer
globenewswire.com
EDAP
TLX
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AZN
MRK
JNJ
PFE
ABBV
GSK
ALLR
SNY
CURI
ORIC
EXEL
ABSI
LLY
TLX
FPH
BMY
SNX
XNCR
ZENA
ARVN
MGNX
DASH
VERU
GILD
EVGN
GEN
AMGN
MIR
RXRX
BG
MTX
BIO
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
globenewswire.com
TLX
TLX101-Px (Pixlumi®) MAA Accepted in Europe
globenewswire.com
TLX